OptimizeRx director granted 34,517 RSUs

WASSON GREGORY D reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

WASSON GREGORY D reported acquisition or exercise transactions in this Form 4 filing.

OptimizeRx Corp director Gregory D. Wasson received an equity award of 34,517 restricted stock units (RSUs). These RSUs represent a contingent right to receive shares of OptimizeRx common stock as part of his director compensation, at no cash purchase price.

The RSUs will vest in full on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. After this grant, Wasson directly holds 91,700 shares of OptimizeRx common stock, reflecting his ongoing equity stake in the company.

Insights

Equity Compensation Analyst

Routine director RSU grant that increases equity-based compensation without immediate market trading.

Director Gregory D. Wasson received 34,517 restricted stock units in OptimizeRx Corp as a share-based award. The footnote explains these RSUs convert into common stock once vested, aligning director incentives with shareholder value through equity ownership rather than cash.

The RSUs vest in full on the earlier of the first anniversary of the grant or the next annual shareholder meeting, creating a short-to-medium-term service and retention period. After this grant, Wasson holds 91,700 shares directly, suggesting the award is a routine addition to an existing position rather than a transformative change.

Insider Trade Summary

Grant/Award: 34,517 shares

Grant/Award 1 txn

Insider WASSON GREGORY D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	34,517	$0.00	$0.00

Holdings After Transaction: Common Stock — 91,700 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders.

Key Figures

RSU grant size: 34,517 units Grant price: $0.0000 per share Shares held after grant: 91,700 shares +3 more

6 metrics

RSU grant size 34,517 units Restricted stock units awarded to director Gregory D. Wasson

Grant price $0.0000 per share Stated transaction price for RSU award

Shares held after grant 91,700 shares Common stock directly owned by Gregory D. Wasson following the transaction

Vesting trigger 1 First anniversary of grant Date when RSUs may fully vest

Vesting trigger 2 Next annual shareholder meeting Alternative date when RSUs may fully vest

Transaction date 2026-06-09 Date of RSU grant

Key Terms

restricted stock units, contingent right, annual meeting of shareholders, common stock, +1 more

5 terms

restricted stock units financial

"Grant of restricted stock units representing a contingent right to receive shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"representing a contingent right to receive shares of OptimizeRx common stock"

annual meeting of shareholders financial

"the date of the Company's next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

common stock financial

"shares of OptimizeRx common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OptimizeRx (OPRX) director Gregory D. Wasson receive in this Form 4?

Gregory D. Wasson received 34,517 restricted stock units (RSUs) of OptimizeRx common stock as an equity award. These RSUs are a form of share-based compensation and convert into common shares once the vesting conditions described in the filing are met.

When do Gregory Wasson’s new OptimizeRx (OPRX) RSUs vest?

The 34,517 restricted stock units vest in full on the earlier of the first anniversary of the grant date or the date of OptimizeRx’s next annual meeting of shareholders. This creates a relatively near-term vesting horizon tied to director service and the shareholder meeting schedule.

How many OptimizeRx (OPRX) shares does Gregory Wasson hold after this transaction?

After the RSU grant, Gregory Wasson directly holds 91,700 shares of OptimizeRx common stock. This total reflects his position following the award and provides context for the scale of the new grant relative to his existing equity holdings in the company.

Was Gregory Wasson’s OptimizeRx (OPRX) RSU grant an open-market purchase?

No, the transaction is coded as a grant or award, not an open-market purchase. The 34,517 restricted stock units were awarded at a stated price of $0.00 per share, meaning they are compensation-based equity and do not represent a cash purchase in the market.

What type of security was involved in this OptimizeRx (OPRX) Form 4 filing?

The filing involves OptimizeRx common stock delivered through restricted stock units. Each RSU represents a contingent right to receive one share of common stock, subject to vesting on the earlier of the first grant anniversary or the company’s next annual meeting of shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 01:37 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WASSON GREGORY D

(Last) (First) (Middle)

C/O OPTIMIZERX CORPORATION

260 CHARLES STREET, SUITE 302

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OptimizeRx Corp [ OPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		34,517(1)	A	$0	91,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.

	/s/ Marion Odence-Ford, by Power of Attorney	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)